Johnson & Johnson, Q4

Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
MassDevice21h
Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...
Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond
Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone ...
TipRanks on MSN3d
Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards
Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...
Jim Cramer on Johnson & Johnson (JNJ): ‘Make Good Money Just By Reinvesting Their Juicy Dividends’
We recently published an article titled Jim Cramer Discussed 9 Stocks for This Week’s Game Plan. In this article, we are ...
Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?
Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the ...